Results 41 to 50 of about 201,919 (214)
Precision medicine to identify, prevent, and treat pediatric obesity [PDF]
Pediatric obesity is a growing health concern that has many secondary adverse health implications. Personalized medicine is a tool that can be used to optimize diagnosis and treatments of many diseases.
Tillman, Emma M., Mertami, Selsbiel
core +1 more source
Background Incretin analogues, used for the treatment of type 2 diabetes mellitus and obesity, such as GLP1-receptor agonist liraglutide (Lira) have been shown to reduce major adverse cardiac events in recent clinical trials of heart failure. Tirzepatide
Zsombor I. Hegedűs +9 more
doaj +1 more source
Background Late and misdiagnoses of rare disease patients are common and often result in medical, physical and mental burden for the patient, and financial and emotional burden for the patient’s family.
Liese Vandeborne +4 more
doaj +1 more source
Pharmacotherapy of Essential Tremor
Essential tremor (ET) is a common movement disorder but its pathogenesis remains poorly understood. This has limited the development of effective pharmacotherapy.
František Cibulcík +2 more
core +1 more source
Background The flipped classroom (FC) approach has demonstrated efficacy in enhancing the learning process, including within higher education contexts such as medical education.
Zsófia Onódi +4 more
doaj +1 more source
Risk Assessment of Drug‐Induced Long QT Syndrome for Some COVID‐19 Repurposed Drugs
The risk‐benefit ratio associated with the use of repurposed drugs to treat severe acute respiratory syndrome‐coronavirus 2 (SARS‐CoV‐2)‐related infectious coronavirus disease 2019 (COVID‐19) is complicated because benefits are awaited, not proven.
Veronique Michaud +6 more
doaj +1 more source
Background Several classification systems for medication errors (MEs) have been established over time, but none of them apply optimally for classifying severe MEs.
Carita Linden-Lahti +3 more
doaj +1 more source
Update on the pharmacotherapy of obesity.
Click on the Resource Link to access the article (may not be free).Objective: To review recent developments in the pharmacotherapy of obesity, including the agents currently approved for use in the management of obesity and those under development. Data
Lomaestro, B M, Malone, M, Cerulli, J
core +1 more source
Conclusion: In patients with stroke, reducing rather than increasing the number of drugs administered during recovery-phase rehabilitation could improve rehabilitation outcomes.
Shunsuke Hanaoka +4 more
doaj +1 more source
Endoplasmic reticulum (ER) stress, caused by the accumulation of unfolded proteins, is involved in the development of obesity. We demonstrated that flurbiprofen, a nonsteroidal anti‐inflammatory drug (NSAID), exhibited chaperone activity, which reduced ...
Toru Hosoi +9 more
doaj +1 more source

